FDA
-
-
-
-
-
-
-
Voyager gets FDA clearance for first tau gene therapy for Alzheimer's
-
-
-
-
-
-
-
Voyager Reports First Quarter 2025 Financial and Operating Results
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Picks Development Candidate for GBA1 Program
-
-
-
-
-
-
-
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurologic
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/23: (OCGN) (UAVS) (SUPN) (CLNE) (CLRB) (FUBO) (NKLA) (more...)
-
-
-
-
-
-
-
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

